IMVT 8-K: SEC filing
Filed with the SEC on · accession 0001764013-26-000121
IMVT filed a 8-K (current report) with the SEC on Nov 9, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Summary of the filing
Immunovant, Inc. furnished a Form 8-K announcing its financial results for the fiscal second quarter and six months ended September 30, 2026, via a press release attached as Exhibit 99.1.
Key details
✦ Ask GOAX AI about this filing — what it means for IMVT, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for IMVT?
Click hereFrequently asked questions
What did IMVT file with the SEC on Nov 9, 2026?
IMVT filed a 8-K (SEC filing). Immunovant, Inc. furnished a Form 8-K announcing its financial results for the fiscal second quarter and six months ended September 30, 2026, via a press release attached as Exhibit 99.1.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other IMVT SEC filings
Get alerts when IMVT files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days